Answers are grounded in this paper and cite their sources.
BACKGROUND: Multiple advanced therapies have been studied in patients with hidradenitis suppurativa (HS), but current treatment guidelines are not able to keep up with the rate of new published evidence for these agents. OBJECTIVE: To develop and apply a framework for living international evidence-based guidelines housed on a dedicated and accessible internet platform for the approach and management of patients with HS. METHODS: A steering committee supervised literature searches, screening, data extraction, and development of statements using the Grading of Recommendations Assessment, Development, and Evaluation framework. An electronic e-Delphi process was used to adopt recommendations using an a priori determined cut-off of 70% agreement. RESULTS: Eighteen experts from 10 countries participated in the e-Delphi voting from September to December 2025. Statements included treatment with inhibitors of tumor necrosis factor, interleukin-17 (IL-17), IL-1, IL-12/IL-23, and Janus kinases. Of 18 recommendations, 11 were adopted in the first round and 6 in the second round. One recommendation was omitted. CONCLUSIONS: These current recommendations provide important practical guidance on the selection and use of advanced therapies in the management of patients with HS, based on current evidence. They include advice for selection of off-label agents when approved medications are contraindicated or fail, and will be updated on an ongoing basis with regularly planned searches to identify and incorporate new data.
No takes yet. Share an insight, caveat, or question.
Sibbald et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: